MCID: PLM129
MIFTS: 62

Pulmonary Disease, Chronic Obstructive

Categories: Genetic diseases, Respiratory diseases, Blood diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 54 71 42 38
Chronic Obstructive Pulmonary Disease 38 29 3
Copd 71 41 3
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 29
Severe Early-Onset Chronic Obstructive Pulmonary Disease 71
Chronic Obstructive Pulmonary Disease of Horses 69
Copd, Rate of Decline of Lung Function in 54
Pulmonary Disease Chronic Obstructive 52
Chronic Obstructive Airway Disease 69
Chronic Obstructive Lung Disease 71

Classifications:



External Ids:

OMIM 54 606963
MeSH 42 D029424
ICD10 33 J44.0 J44.8
SNOMED-CT via HPO 65 13645005

Summaries for Pulmonary Disease, Chronic Obstructive

MedlinePlus : 41 copd (chronic obstructive pulmonary disease) makes it hard for you to breathe. the two main types are chronic bronchitis and emphysema. the main cause of copd is long-term exposure to substances that irritate and damage the lungs. this is usually cigarette smoke. air pollution, chemical fumes, or dust can also cause it. at first, copd may cause no symptoms or only mild symptoms. as the disease gets worse, symptoms usually become more severe. they include a cough that produces a lot of mucus shortness of breath, especially with physical activity wheezing chest tightness doctors use lung function tests, imaging tests, and blood tests to diagnose copd. there is no cure. treatments may relieve symptoms. they include medicines, oxygen therapy, surgery, or a lung transplant. quitting smoking is the most important step you can take to treat copd. nih: national heart, lung, and blood institute

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to pulmonary hypertension and asthma, and has symptoms including chronic obstructive pulmonary disease, angina pectoris and coughing. An important gene associated with Pulmonary Disease, Chronic Obstructive is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and Transcriptional misregulation in cancer. The drugs Advair and Anoro Ellipta have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and cardiovascular system

OMIM : 54
Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

UniProtKB/Swiss-Prot : 71 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

Wikipedia : 72 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
id Related Disease Score Top Affiliating Genes
1 pulmonary hypertension 31.0 MMP1 TNF
2 asthma 29.1 ADAM33 ADRB2 CXCL8 ELANE IL6 MMP1
3 respiratory failure 11.3
4 aspergillosis 11.3
5 hypoxia 11.2
6 multifocal atrial tachycardia 11.2
7 bloom syndrome 10.9
8 alpha 1-antitrypsin deficiency 10.9
9 nontuberculous mycobacterial lung disease 10.9
10 lung disease 10.8
11 myopathy 10.6 CXCL8 MMP1 TNF
12 venezuelan equine encephalitis 10.6 CXCL8 ELANE SERPINA1
13 basidiobolomycosis 10.5 CXCL8 TNF
14 hemoglobin lepore-beta-thalassemia syndrome 10.5 ELN MMP1
15 tibialis tendinitis 10.5 CXCL8 PTGS1 TNF
16 burns 10.5 CXCL8 ELANE RNASE3
17 papular elastorrhexis 10.5 ELANE ELN MMP12
18 mycobacterium kansasii 10.5 CXCL8 HMOX1 SERPINA1 TNF
19 cardiocranial syndrome 10.5 CRP CXCL8 ELANE
20 dehydration polycythemia 10.4 CXCL8 RNASE3 TNF
21 pelvic varices 10.4 CXCL8 RNASE3 TNF
22 tetanus 10.4 ELANE ELN TNF
23 fuchs' heterochromic uveitis 10.4 CXCL8 RNASE3 TNF
24 smarca4-deficient sarcoma of thorax 10.4 IL6 TNF
25 oculomotor nerve paralysis 10.4 CXCL8 IL6
26 alcoholic pancreatitis 10.4 ELANE ELN RNASE3
27 louping ill 10.3 CRP CXCL8 TNF
28 common peroneal nerve lesion 10.3 CXCL8 IL6
29 exophthalmos 10.3 ADRB2 CXCL8 ELANE RNASE3
30 osteogenesis imperfecta, type x 10.3 CXCL8 IL6 MMP1
31 whistling face syndrome, recessive form 10.3 CRP CXCL8 RNASE3
32 anal fistula 10.3 CXCL8 ELANE ELN SERPINA1
33 sheehan syndrome 10.3 CRP CXCL8 TNF
34 cholera 10.3 ELANE IL6 MMP1
35 labyrinthine bilateral reactive loss 10.3 CXCL8 ELANE IL6
36 uterine corpus dissecting leiomyoma 10.3 ADRB2 CXCL8 IL6
37 aortic arch interruption 10.3 IL6 TNF
38 anencephaly and spina bifida x-linked 10.2 IL6 SERPINA1 TNF
39 signet ring cell adenocarcinoma 10.2 CRP RNASE3 TNF
40 spirillary rat-bite fever 10.2 CXCL8 IL6 TNF
41 facial dermatosis 10.2 CRP RNASE3 TNF
42 cutaneous leishmaniasis 10.2 IL6 TNF
43 chronic conjunctivitis 10.2
44 rheumatic myocarditis 10.2 IL6 MMP1 TNF
45 pasteurellosis 10.2 CXCL8 IL6 TNF
46 collagenopathy type 2 alpha 1 10.2 CRP IL6
47 tricho onychic dysplasia 10.2 CXCL8 IL6 TNF
48 pyelonephritis 10.2 CRP CXCL8 HMOX1 TNF
49 intra-abdominal lymph node mast cell malignancy 10.2 CRP CXCL8 MMP1 TNF
50 dysphagia 10.2 CXCL8 IL6 TNF

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Clinical features from OMIM:

606963

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

32
id Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 32 HP:0006510

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


angina pectoris, coughing, snoring, tremor, equilibration disorder

MGI Mouse Phenotypes related to Pulmonary Disease, Chronic Obstructive:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 GC HDAC2 HMOX1 IL6 MMP1 MMP12
2 cardiovascular system MP:0005385 10.07 ADRB2 CHRM3 CRP CXCR2 HDAC2 HMOX1
3 endocrine/exocrine gland MP:0005379 9.97 HMOX1 IL6 PTGS1 TNF ADRB2 CHRM3
4 immune system MP:0005387 9.9 ELANE HDAC2 HMOX1 IL6 MMP1 MMP12
5 neoplasm MP:0002006 9.56 CXCR2 ELANE EPHX1 HDAC2 IL6 MMP1
6 respiratory system MP:0005388 9.23 CHRM3 CXCR2 HDAC2 HMOX1 IL6 MMP12

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

FDA approved drugs:

(show all 16)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Advair 17 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
2
Anoro Ellipta 17 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GlaxoSmithKline December of 2013
3
Arcapta 17 INDACATEROL MALEATE Novartis July 2011
4
Breo Ellipta 17 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE GlaxoSmithKline May 2013
5
Brovana 17 ARFORMOTEROL TARTRATE Sepracor in October 2006
6
Daliresp 17 ROFLUMILAST Forest Pharmaceuticals February 2011
7
DuoNeb 17 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
8
Foradil Aerolizer 17 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Incruse Ellipta 17 UMECLIDINIUM BROMIDE GlaxoSmithKline May 2014
10
Rayos 17 PREDNISONE Horizon Pharma July of 2012
11
Spiriva HandiHaler 17 TIOTROPIUM BROMIDE Boehringer Ingelheim February 2004
12
Stiolto Respimat 17 OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE Boehringer Ingelheim May 2015
13
Striverdi Respimat 17 OLODATEROL HYDROCHLORIDE Boehringer Ingelheim July 2014
14
Tudorza Pressair 17 ACLIDINIUM BROMIDE Forest Laboratories July 2012
15
Utibron Neohaler 17 GLYCOPYRROLATE ; INDACATEROL MALEATE Novartis October 2015
16
Xopenex 17 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 633)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 55185 53477736 447043
2
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 1 78919-13-8 6443959
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
6
Terbutaline Approved Phase 4,Phase 3 23031-25-6 5403
7
Metoprolol Approved, Investigational Phase 4,Phase 3 37350-58-6, 51384-51-1 4171
8
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51333-22-3 63006 5281004
9
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
10
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
11
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
12
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1 22254-24-6, 60205-81-4 43232
13
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3 564-25-0 54671203
14
Cefuroxime Approved Phase 4,Phase 3 55268-75-2 5361202 5479529
15
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85721-33-1 2764
16
Clarithromycin Approved Phase 4,Phase 3,Early Phase 1 81103-11-9 84029
17
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
18
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
19
Piperacillin Approved Phase 4 66258-76-2 43672
20
Tazobactam Approved Phase 4 89786-04-9 123630
21
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
22
Theophylline Approved Phase 4,Phase 3,Phase 2 58-55-9 2153
23
Fenoterol Approved Phase 4,Phase 3 13392-18-2 3343
24
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
26
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
27
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
28 Racepinephrine Approved Phase 4
29
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
30
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
31
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
33
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
34
Norgestimate Approved Phase 4,Phase 3,Phase 1 35189-28-7 6540478
35
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
37
Metformin Approved Phase 4 657-24-9 14219 4091
38
Adenosine Approved, Investigational Phase 4,Phase 2 58-61-7 60961
39
Regadenoson Approved Phase 4 313348-27-5 219024
40
Infliximab Approved Phase 4,Phase 3 170277-31-3
41
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
42 Olodaterol Approved Phase 4,Phase 3,Phase 2,Phase 1 868049-49-4
43
Fosinopril Approved Phase 4 98048-97-6 55891
44
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
45
Acetazolamide Approved, Vet_approved Phase 4,Phase 3 59-66-5 1986
46
Oxymetazoline Approved Phase 4,Phase 3,Phase 2,Phase 1 1491-59-4 4636
47
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 59-42-7 6041
48
Ketoconazole Approved, Investigational Phase 4,Phase 1 65277-42-1 47576 3823
49
Selenium Approved, Vet_approved Phase 4,Phase 3 7782-49-2
50
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444

Interventional clinical trials:

(show top 50) (show all 3021)

id Name Status NCT ID Phase Drugs
1 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
2 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
5 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
6 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
7 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
8 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
9 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
10 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
11 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
12 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
13 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
14 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
15 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
16 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
17 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
18 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
19 The Effects of Continuous Positive Airway Pressure on Overlap Syndrome Unknown status NCT00914264 Phase 4
20 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
21 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
22 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
23 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
24 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
25 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
26 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
27 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
28 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
29 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
30 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
31 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
32 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
33 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
34 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
35 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
36 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
37 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
38 Airway Clearance for Prevention of COPD Exacerbation Unknown status NCT00181207 Phase 4
39 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
40 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
41 Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00984659 Phase 4 Fluticasone propionate/salmeterol combination product;Salmeterol;Placebo
42 Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations Completed NCT00115492 Phase 4 Fluticasone Propionate/Salmeterol Combination Product;Salmeterol
43 ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the Completed NCT00144911 Phase 4 Salmeterol;Fluticasone Propionate/Salmeterol Combination Product
44 Metformin in Chronic Obstructive Pulmonary Disease Completed NCT01247870 Phase 4 Metformin;Placebo
45 Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies. Completed NCT00355342 Phase 4 fluticasone propionate/salmeterol powder;salmeterol powder
46 A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease Completed NCT00862641 Phase 4 Regadenoson;Placebo
47 Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease Completed NCT00106821 Phase 4 Tiotropium Bromide Inhalation Powder
48 Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease Completed NCT01124422 Phase 4 fluticasone propionate/salmeterol inhalation powder DISKUS 250/50;tiotropium bromide inhalation powder HandiHaler
49 Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD). Completed NCT00523991 Phase 4 tiotropium;Placebo
50 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00975195 Phase 4 tiotropium inhalation;salmeterol xinafoate;fluticasone propionate;placebo matched for fluticasone propionate

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Pulmonary Disease, Chronic Obstructive:
Adipocell
Bone marrow-derived mononuclear cells for chronic obstructive pulmonary disease
Prochymal
StempeucelCOPD
Embryonic/Adult Cultured Cells Related to Pulmonary Disease, Chronic Obstructive:
Bone marrow-derived mononuclear cells PMIDs: 21653527 23054962 21311694
Bone marrow-derived mesenchymal stem cells PMIDs: 23172272 21653527
Bone marrow-derived mesenchymal stem cells (Stempeucel PMIDs: 18720444

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

id Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 29
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 29

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

39
Lung, Testes, Heart, Endothelial, Bone, Smooth Muscle, Neutrophil

Publications for Pulmonary Disease, Chronic Obstructive

Variations for Pulmonary Disease, Chronic Obstructive

Copy number variations for Pulmonary Disease, Chronic Obstructive from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 230707 8 1 12700000 Copy number DEFB4 Chronic obstructive pulmonary disease

Expression for Pulmonary Disease, Chronic Obstructive

Search GEO for disease gene expression data for Pulmonary Disease, Chronic Obstructive.

Pathways for Pulmonary Disease, Chronic Obstructive

Pathways related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.22 CXCL8 IL6 MMP1 TNF
2 12.13 CXCL8 ELANE HDAC2 IL6
3 12.07 IL6 MMP1 MMP12 TNF
4 11.84 CXCL8 IL6 MMP12 TNF
5 11.78 CXCL8 IL6 TNF
6 11.76 CXCL8 IL6 TNF
7
Show member pathways
11.73 ELANE MMP1 MMP12 TNF
8 11.71 CXCL8 HMOX1 IL6 MMP1 TNF
9 11.66 CXCL8 IL6 TNF
10 11.66 CXCL8 IL6 MMP1 TNF
11 11.58 CXCL8 HDAC2 IL6 MMP1
12 11.55 CXCL8 MMP1 MMP12
13 11.48 CXCL8 IL6 TNF
14 11.44 CXCL8 IL6 MMP1
15
Show member pathways
11.42 CXCL8 IL6 MMP1 TNF
16 11.4 CXCL8 IL6 TNF
17 11.39 CXCL8 IL6 TNF
18 11.37 ELANE IL6 TNF
19 11.26 ELANE ELN MMP1
20 11.23 CXCL8 ELN HMOX1 IL6 SERPINA1 TNF
21 11.2 HMOX1 IL6 TNF
22 10.99 CXCL8 HMOX1 IL6 MMP1
23 10.38 CRP CXCL8 HMOX1 IL6 PTGS1 TNF

GO Terms for Pulmonary Disease, Chronic Obstructive

Cellular components related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CRP CXCL8 ELANE ELN GC IL6
2 extracellular space GO:0005615 9.32 CRP CXCL8 ELANE GC HMOX1 IL6

Biological processes related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.73 CRP CXCL8 CXCR2 IL6 PTGS1 TNF
2 defense response to Gram-positive bacterium GO:0050830 9.62 CRP IL6 RNASE3 TNF
3 acute-phase response GO:0006953 9.58 CRP IL6 SERPINA1
4 positive regulation of chemokine biosynthetic process GO:0045080 9.52 HMOX1 TNF
5 response to caffeine GO:0031000 9.51 HDAC2 IL6
6 neutrophil activation GO:0042119 9.49 CXCL8 CXCR2
7 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.48 ELANE TNF
8 response to yeast GO:0001878 9.46 ELANE IL6
9 extracellular matrix disassembly GO:0022617 9.46 ELANE ELN MMP1 MMP12
10 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.43 IL6 TNF
11 negative regulation of chemokine biosynthetic process GO:0045079 9.37 ELANE IL6
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.26 ELANE HMOX1 IL6 TNF
13 negative regulation of lipid storage GO:0010888 8.8 CRP IL6 TNF

Molecular functions related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 ELANE MMP1 MMP12

Sources for Pulmonary Disease, Chronic Obstructive

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
12